Download Report Global Personalized Cancer Vaccine Market Opportunity and Clinical Innovation Trend Outlook 2024

“Global Personalized Cancer Vaccine Market Opportunity and Clinical Innovation Trend Outlook 2024” Report Highlights:

* General Working Mechanism of Personalized Cancer Vaccine
* Relevance of Biomarkers In Personalized Vaccines
* Developmental Cost Analysis of a Personalized Cancer Vaccine
* Advancements in the Personalized Cancer Vaccine
* Personalized Cancer Vaccine Market Analysis by Cancer

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-personalized-cancer-vaccine-market-opportunity-and-clinical-innovation-trend-outlook-2024.php

Table of Contents

1. Personalized Cancer Vaccine: Promising Cancer Therapeutics of the Future
1.1 The Possibility of a Cancer Vaccine
1.2 Cancer Vaccines - An Insight into its Current Clinical Status

2. General Working Mechanism of Personalized Cancer Vaccine
2.1 Entities of A personalized Cancer Vaccine and Their Respective Roles
2.1.1 Tumor Neo - Antigens
2.1.2 Human Leukocyte Antigen
2.2 Personalized Cancer Vaccine in Action
2.3 Pharmacogenomics towards Genomic Polymorphism
2.4 Somatic Mutations in Cancer Pharmacogenomics

3. Relevance of Biomarkers In Personalized Vaccines
3.1 Pharmacogenomic Biomarkers
3.2 Prognostic and Predictive Biomarkers
3.3 Immune Checkpoint Biomarkers

4. Manufacturing Process and Cost Analysis of a Personalized Cancer Vaccine
4.1 Pre - Manufacturing Cost Analysis
4.2 Manufacturing Cost Analysis of Personalized Cancer Vaccine
4.2.1 Capital Cost
4.2.2 Cost of Raw Materials
4.2.3 Annual Cost of Personnel Involved in Cancer Vaccine Manufacture
4.2.4 Factory and Administrative Overheads
4.2.5 Filling and Packaging
4.3 Personalized Cancer Vaccine Cost per Patient

5. Current Market Trends and Advancements in the Personalized Cancer Vaccine Segment
5.1 Breakthrough Research Improving the Outcome of Future Personalized Cancer Vaccine
5.2 Rising Investments in the Personalized Cancer Vaccine Market
5.3 Use of mRNA for the Development of Personalized Cancer Vaccine
5.4 Collaborations and Ventures Ensure Stable Funding to the Personalized Cancer Vaccine Market
5.5 Advancement in DNA Sequencing Technology to Drive the Personalized Cancer Vaccine Market

6. Global - Personalized Cancer Vaccine Market Analysis by Cancer Type
6.1 Melanoma
6.2 Lung Cancer
6.3 Breast Cancer
6.4 Colorectal Cancer
6.5 Leukemia
6.6 Prostate Cancer
6.7 Cervical Cancer
6.8 Glioblastoma (Brain Tumor)

7. New Avenues and Opportunities for Personalized Cancer Vaccine Development
7.1 Commercial Insights into the Personalized Cancer Vaccine Pipeline
7.2 Opportunities in the Emerging Market

8. Porter’s Five Force Analysis of the Personalized Cancer Vaccine Market
8.1 Bargaining Power of Suppliers
8.2 Bargaining Power of Buyer
8.3 Threats of Substitute Products
8.4 Threat of New Entrants
8.5 Rivalry Among the Existing Competitors

9. Driving Factors of the Personalized Cancer Vaccine Market
9.1 Increasing Need for Personalized Cancer Vaccine Production
9.2 Alarming Increase in the Number of Cancer Incidences
9.3 Cancer Heterogenetic Environment
9.4 High Level of Specificity
9.5 Assistance from Government
9.6 Improvement in Genome Sequencing Techniques
9.7 Robust Clinical Pipeline Under Development

10. Major Challenges to the Personalized Cancer Vaccine Market
10.1 Scientific and Technical Challenges in Developing a Personalized Cancer Vaccine
10.2 Commercialization Challenges

11. Global Personalized Cancer Vaccine Market Future Outlook

12. Competitive Landscape
12.1 Advaxis Inc.
12.2 Avax Technologies
12.3 BioNtech AG
12.4 Celldex
12.5 CureVac AG
12.6 Genetech
12.7 Genocea
12.8 Gristone Oncology
12.9 ISA Pharmaceuticals
12.10 Merck
12.11 Moderna Therapeutics
12.12 Neon Therapeutics
12.13 Personalise

Figure 1-1: Cancer Immunotherapeutics in the Development of Cancer Vaccine
Figure 1-2: Advantages of Targeting Neo - Antigens in Cancer Vaccine Production
Figure 2-1: Mechanism of Action of a Personalized Cancer Vaccine
Figure 2-2: Demonstration of Genomic Polymorphism in Pharmacogenomics
Figure 2-3: The Sources of Pharmacological and Pharmacogenetic Variability’s
Figure 3-1: Illustration of Various Types of Biomarkers in Personalized Medicine
Figure 3-2: Roadmap of Development of Predictive Biomarkers
Figure 3-3: High Throughput Immune Assessment for Biomarker Discovery
Figure 4-1: General Overview of Personalized Cancer Vaccine Production
Figure 4-2: Pre - Manufacturing Cost Analysis for Personalized Cancer Vaccine (US$), 2018
Figure 4-3: Gardasil - Annualized Capital Cost of Production (US$ Million), 2018
Figure 4-4: Cervarix - Annualized Capital Cost of Production (US$ Million), 2018
Figure 4-5: Gardasil - Raw Material Cost Analysis (US$ Million), 2018
Figure 4-6: Cervarix - Raw Material Cost Analysis (US$ Million), 2018
Figure 4-7: Gardasil - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 4-8: Cervarix - Annual Cost of Personnel Involved in Cancer Vaccine Manufacture (US$ Million), 2018
Figure 4-9: Gardasil - Factory and Administrative Overheads (US$ Million), 2018
Figure 4-10: Cervarix - Factory and Administrative Overheads (US$ Million), 2018
Figure 4-11: Gardasil - Manufacturing Cost per single Dose (US$), 2018
Figure 4-12: Cervarix - Manufacturing Cost per single Dose (US$), 2018
Figure 4-13: Personalized Cancer Vaccine - Treatment Cost (US$/Patient), 2018
Figure 4-14: Global - HPV Vaccine Adoption Rate by Regions (%), 2018
Figure 4-15: Gardasil and Gardasil 9 - Cost Analysis (US$), 2018
Figure 5-1: Trends and Advancement in the Personalized Cancer Vaccine Segment
Figure 5-2: Investments Generated by Key Market Players in the Personalized Cancer Segment (US$ Million), 2018
Figure 6-1: Alteration in CDKN2A Mechanism
Figure 6-2: Global - Melanoma and Non - Melanoma Cancer Incidence (000’), 2018
Figure 6-3: Global - Melanoma Prevalence by Region (%), 2018
Figure 6-4: Global - Lung Cancer Incidence (in 000’), 2018
Figure 6-5: Global - Lung Cancer Prevalence by Region (%), 2018
Figure 6-6: Global - Breast Cancer Incidence (000’), 2018
Figure 6-7: Global - Breast Prevalence by Region (%), 2018
Figure 6-8: Global - Colorectal Cancer Incidence (000’) 2018
Figure 6-9: Global - Colorectal Cancer Market Size (%), 2018
Figure 6-10: Global - Leukemia Incidence (000’), 2018
Figure 6-11: Global - Leukemia Market Size (%), 2018
Figure 6-12: Global - Prostate Cancer Incidence (000’), 2018
Figure 6-13: Global - Prostate Cancer Prevalence by Region (%), 2018
Figure 6-14: Provenge - Cost Analysis (US$/Month)
Figure 6-15: Global - Cervical Cancer Incidence (000’), 2018
Figure 6-16: Global - Cervical Cancer prevalence by Region (%), 2018
Figure 7-1: Global - Oncology Market Size by Region (%), 2017
Figure 8-1: Porter’s Five Force Analysis - Overview
Figure 9-1: Driving Factors of the Personalized Cancer Vaccine Market
Figure 9-2: Global - Most Common Types of Cancer by Prevalence, 2018
Figure 9-3: Decrease in the Cost of Human Genome Sequencing (US$/Patient), 2018
Figure 9-4: Time Taken in Whole Genome Sequencing (Months/Patient), 2018
Figure 10-1: Scientific Limitations in Personalized Cancer Vaccine Development
Figure 11-1: Global - Gardasil Sales Forecast (US$ Billion), 2018 -2024
Figure 11-2: Cervarix - Future Sales Forecast (US$ Billion), 2018 - 2024
Figure 11-3: Global - Personalized Cancer Vaccine Market Opportunity (US$ Billion), 2018 - 2024






Table 5-1: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
Table 5-2: Personalized Strategies to Attain Target in Acute Myeloid Leukemia

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.